UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 2, 2005

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed

all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter

period that the registrant was required to file such reports) and (2) has

been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is an

accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES X NO

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At November 4, 2005, 7,371,396,380 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

October 2, 2005

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements:

Condensed

Consolidated Statements of Income for the three months and nine months ended October 2,

2005 and September 26, 2004

Condensed

Consolidated Balance Sheets at October 2, 2005 and

December 31, 2004

Condensed

Consolidated Statements of Cash Flows for the nine months ended October 2,

2005 and September 26, 2004

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

18

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

19

Item 4.

Controls and

Procedures

47

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

47

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

50

Item 6.

Exhibits

50

Signature

51

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(millions

of dollars, except per common share data)

Oct. 2,

2005

Sept. 26,

2004

Oct. 2,

2005

Sept. 26,

2004

Revenues

12,189

12,831

37,705

37,593

Costs

and expenses:

Cost of sales(a)

1,908

1,640

6,180

5,185

Selling, informational and administrative expenses(a)

3,931

4,036

12,242

12,227

Research and development expenses(a)

1,783

1,888

5,421

5,356

Amortization of intangible assets(a)

836

843

2,576

2,496

Merger-related in-process research and development

charges

1,390

--

1,652

955

Restructuring charges and merger-related costs

307

190

796

726

Other (income)/deductions - net

(163)

283

669

140

Income from continuing operations before provision

for taxes on income, and minority interests

2,197

3,951

8,169

10,508

Provision

for taxes on income

591

650

2,815

2,040

Minority interests

Income from continuing operations

1,602

3,298

5,345

8,461

Discontinued operations:

(Loss)/income from discontinued operations - net

of tax

(16)

(3)

(37)

27

Gains on sales of discontinued operations - net

of tax

46

44

48

Discontinued operations - net of tax

(13)

43

75

Net income

1,589

3,341

5,352

8,536

Earnings

per common share - Basic:

Income from continuing operations

0.22

0.44

0.73

1.12

Discontinued operations - net of tax

--

0.01

--

0.01

Net income

0.22

0.45

0.73

1.13

Earnings

per common share - Diluted:

Income from continuing operations

0.22

0.43

0.72

1.11

Discontinued operations - net of tax

--

0.01

--

0.01

Net income

0.22

0.44

0.72

1.12

Weighted-average shares used to calculate earnings per

common share:

Basic

7,333

7,501

7,372

7,554

Diluted

7,382

7,569

7,424

7,642

Cash

dividends paid per common share

0.19

0.17

0.57

0.51

(a)

Includes

amortization of intangible assets, as disclosed in Note 11B,

Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

Oct. 2,

2005*

Dec. 31,

2004**

ASSETS

Current Assets

Cash and cash

equivalents

959

1,808

Short-term

investments

12,430

18,085

Accounts

receivable, less allowance for doubtful accounts: 2005 - $181;

2004 - $205

9,348

9,367

Short-term

loans

611

653

Inventories

6,556

6,660

Prepaid

expenses and taxes

2,724

2,939

Assets held for

sale

140

182

Total current assets

32,768

39,694

Long-term

investments and loans

2,784

3,873

Property, plant

and equipment, less accumulated depreciation:

2005 - $9,199; 2004 - $8,534

17,519

18,385

Goodwill

23,806

23,756

Identifiable

intangible assets, less accumulated amortization

28,976

33,251

Other assets,

deferred taxes and deferred charges

4,490

4,725

Total assets

110,343

123,684

LIABILITIES

AND SHAREHOLDERS' EQUITY

Current Liabilities

Short-term

borrowings, including current portion of long-term debt:

2005 - $1,401; 2004 - $907

6,729

11,266

Accounts

payable

1,809

2,672

Dividends payable

1,418

Income taxes

payable

4,226

1,963

Accrued

compensation and related items

1,636

1,939

Other current

liabilities

5,990

7,136

Liabilities

held for sale

64

Total current liabilities

20,395

26,458

Long-term debt

5,414

7,279

Pension benefit

obligations

2,771

2,821

Postretirement

benefit obligations

1,442

1,450

Deferred taxes

on income

10,780

12,632

Other

noncurrent liabilities

2,734

4,766

Total liabilities

43,536

55,406

Shareholders' Equity

Preferred stock

175

193

Common stock

439

438

Additional

paid-in capital

67,530

67,098

Employee

benefit trust, at fair value

(970)

(1,229)

Treasury stock

(39,385)

(35,992)

Retained

earnings

38,033

35,492

Accumulated

other comprehensive income

985

2,278

Total shareholders' equity

66,807

68,278

Total liabilities and shareholders'

equity

110,343

123,684

* Unaudited.

** Condensed from audited

financial statements.

See accompanying Notes

to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(millions

of dollars)

Oct. 2,

2005

Sept. 26,

2004

Operating Activities:

Net income

5,352

8,536

Adjustments to reconcile net income to net cash

provided by continuing operating activities:

Discontinued operations - net of tax

(7)

(75)

Depreciation and amortization

4,143

3,782

Merger-related in-process research and development

charges

1,652

955

Asset impairment charge and other costs associated

with the suspension of Bextra sales

1,216

--

Deferred taxes

(279)

(471)

Other

193

479

Changes in assets and liabilities (net of businesses

acquired and divested)

(2,274)

(2,856)

Net

cash provided by continuing operating activities

9,996

10,350

Investing

Activities:

Purchases of property, plant and equipment

(1,493)

(1,526)

Purchases of short-term investments

(16,840)

(11,369)

Proceeds from redemptions of short-term investments

23,179

6,427

Purchases of long-term investments

(650)

(1,132)

Proceeds from sales of long-term investments

655

1,432

Purchases of other assets

(392)

(613)

Proceeds from sales of other assets

267

Acquisitions, net of cash acquired

(2,104)

(1,443)

Proceeds from the sales of businesses and product

lines

108

1,192

Other investing activities

238

32

Net

cash provided by/(used in) investing activities

2,707

(6,733)

Financing

Activities:

Increase in short-term borrowings, net

2,094

Principal payments on short-term borrowings

(5,274)

(238)

Proceeds from issuances of long-term debt

2,592

Principal payments on long-term debt

(1,042)

(29)

Proceeds from common stock issuances

45

53

Purchases of common stock

(3,415)

(4,787)

Cash dividends paid

(4,177)

(3,821)

Stock option transactions and other

301

856

Net cash used in financing activities

(13,548)

(3,280)

Effect of exchange-rate changes on cash and cash

equivalents

(4)

Net (decrease)/increase in cash and cash equivalents

(849)

344

Cash and cash equivalents at beginning of period

1,808

1,520

Cash and cash equivalents at end of period

959

1,864

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

3,738

2,374

Interest

485

312

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1: Basis of Presentation

General

We prepared the condensed consolidated financial statements

following the requirements of the Securities and Exchange Commission (SEC) for

interim reporting. As permitted under those rules, certain footnotes or other

financial information that are normally required by accounting principles

generally accepted in the United States of America (GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month and nine-month periods ended

August 28, 2005 and August 22, 2004. The fiscal first quarter and nine

months of 2005 had three additional business days compared to the fiscal first

quarter and nine months of 2004.

We made certain reclassifications to the 2004 condensed

consolidated financial statements to conform to the 2005 presentation.

Revenues, expenses, assets and liabilities can vary during

each quarter of the year. Therefore, the results and trends in these interim

financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements

included in this document. The financial statements include all normal and

recurring adjustments that are considered necessary for the fair presentation

of our financial position and operating results.

The information included in this Quarterly Report on

Form 10-Q should be read in conjunction with the consolidated financial

statements and accompanying notes included in Pfizer's Annual Report on

Form 10-K for the year ended December 31, 2004.

Share-Based Payments

In accordance with Statement of Financial Accounting

Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, we

elect to account for our stock-based compensation under Accounting Principles

Board Opinion No. 25, Accounting for Stock Issued to Employees. The

exercise price of stock options granted equals the market price on the date of

grant; as such, there is no recorded compensation expense related to grants of

stock options.

The weighted-average fair value

per stock option granted was $5.00 and $6.33 for the three months ended October 2,

2005 and September 26, 2004, and $5.15 and $6.88 for the nine months ended

October 2, 2005 and September 26, 2004. We estimated the fair values,

as required under GAAP, using the Black-Scholes option-pricing model, modified

for dividends and using the assumptions below. Pro forma compensation expense

related to stock options subject to accelerated vesting upon retirement is

recognized over the period of employment up to the vesting date of the grant.

In the first quarter of 2005, we changed our method of estimating expected

dividend yield from historical patterns of dividend payments to a method that

reflects a constant dividend yield during the expected term of the option.

Three Months Ended

Nine Months Ended

Oct. 2,

2005

Sept. 26,

2004

Oct. 2,

2005

Sept. 26,

2004

Expected dividend yield

2.76%

2.98%

2.90%

2.90%

Risk-free interest rate

3.81%

3.36%

3.96%

3.32%

Expected stock price volatility

20.00%

22.88%

21.93%

22.15%

Expected term until exercise

(years)

5.59

5.64

5.75

5.75

The following table shows the

effect on results for the three-month and nine-month periods ended October 2,

2005 and September 26, 2004 if we had applied the fair-value-based

recognition provisions of SFAS 123 to measure stock-based compensation

expense for the option grants:

Three

Months Ended

Nine

Months Ended

(millions

of dollars, except per common share data)

Oct. 2,

2005

Sept. 26,

2004

Oct. 2,

2005

Sept. 26,

2004

Net income

available to common shareholders used in the calculation of basic earnings

per common share:

As reported

under GAAP*

1,588

3,340

5,348

8,532

Compensation

expense - net of tax

(104)

(148)

(356)

(421)

Pro forma

1,484

3,192

4,992

8,111

Basic earnings

per common share:

As reported

under GAAP*

0.22

0.45

0.73

1.13

Compensation

expense - net of tax

(0.02)

(0.02)

(0.05)

(0.06)

Pro forma

0.20

0.43

0.68

1.07

Net income

available to common shareholders used in the calculation of diluted earnings

per common share:

As reported

under GAAP*

1,588

3,340

5,349

8,531

Compensation

expense - net of tax

(104)

(148)

(356)

(421)

Pro forma

1,484

3,192

4,993

8,110

Diluted

earnings per common share:

As reported

under GAAP*

0.22

0.44

0.72

1.12

Compensation

expense - net of tax

(0.02)

(0.02)

(0.05)

(0.06)

Pro forma

0.20

0.42

0.67

1.06

Includes

stock-based compensation expense, net of related tax benefits, of $81 million

for the nine months ended October 2, 2005 ($28 million for the

three months ended October 2, 2005) and $40 million for the nine

months ended September 26, 2004 (none for the three months ended

September 26, 2004).

Net income available to common shareholders used in the

calculation of basic earnings per common share represents net income reduced by

preferred stock dividends - net of tax. Net income available to

common shareholders used in the calculation of diluted earnings per common

share represents net income reduced by the incremental allocation of shares to

the Employee Stock Ownership Plans (ESOPs) acquired as part of the Pharmacia

acquisition.

Note 2: Asset Impairment Charge and Other

Costs Associated with the Suspension of Bextra Sales

In the first nine months of 2005, we recorded charges

totaling $1.2 billion ($762 million, net of tax) in connection with the

decision to suspend sales and marketing of Bextra. This decision resulted from

an April 7, 2005 request from the U.S. Food and Drug Administration (FDA),

as part of its safety review of all COX-2 medicines.

The pre-tax charges included

$1.1 billion related to the impairment of developed technology rights

associated with Bextra and $7 million related to the write-off of

machinery and equipment, both of which are included in Other

(income)/deductions - net. In addition, in connection with the

suspension, we also recorded $56 million in write-offs of inventory and

exit costs, included in Cost of sales; $8 million related to the

costs of administering the suspension of sales, included in Selling,

informational and administrative expenses; and $212 million for an

estimate of customer returns, primarily included against Revenues.

Substantially all of these charges were recorded in the first quarter of 2005.

Note 3: Income Taxes

Income Tax Charge Associated with Repatriation Decision

In the first nine months of 2005, we recorded an income tax

charge of $1.7 billion, included in Provision for taxes on income,

in connection with our decision to repatriate about $36.7 billion of

foreign earnings in accordance with the American Jobs Creation Act of 2004

(the Jobs Act). In the first quarter of 2005, we recorded an initial estimated

income tax charge of $2.2 billion based on the decision to repatriate $28.3 billion

of foreign earnings; in the second quarter of 2005, we reduced our original

estimate of the tax charge by $863 million and revised the repatriation of

foreign earnings to $28.1 billion, principally as a result of guidance

issued by the U.S. Treasury in May 2005. In the second quarter of 2005, we also

recorded an additional tax charge of $373 million, primarily due to our

decision to repatriate an additional $8.6 billion of foreign earnings.

As of October 2, 2005, we intend to continue to permanently

reinvest the earnings of our international subsidiaries and, therefore, we have

not recorded a U.S. tax provision on the remaining amount of unremitted

earnings.

Tax Contingencies

In the second quarter of 2005, we recorded a tax benefit of

$586 million primarily related to the resolution of certain tax positions.

We believe that the IRS audits of the Pfizer Inc. tax returns for the years

1999-2001 and the Warner-Lambert Company tax returns for the years 1999 through

the date of the merger with Pfizer (June 19, 2000) are substantially

complete. In connection with those audits, we are currently in the process of

appealing one matter related to the tax deductibility of a breakup fee paid by

Warner-Lambert Company in 2000.

The IRS has commenced the audit of the Pfizer Inc. tax returns

for the years 2002, 2003 and 2004. The 2005 tax year is also currently under

audit.

As previously disclosed, with respect to Pharmacia

Corporation (formerly known as Monsanto Company), the IRS has completed and

closed its income tax return examinations and appeals through 1999 and has

commenced the audit of the tax returns for the years 2000 through the date of

merger with Pfizer (April 16, 2003).

We periodically reassess the likelihood of assessments

resulting from audits of federal, state and foreign income tax filings. We

believe that our accruals for tax liabilities are adequate for all open years.

Note 4: Adapting to Scale Initiative

We incurred the following costs

in connection with our Adapting to Scale (AtS) initiative, which was announced

in the second quarter of 2005:

(millions

of dollars)

Three

Months

Ended

Oct. 2,

2005

Nine

Months

Ended

Oct. 2,

2005

Implementation